Coherus BioSciences Inc. (CHRS)
$1.42
$0.05
(3.65%)
As on 02-Sep-2026 16:00EDT
Market cap
$218 Mln
Revenue (TTM)
$51 Mln
P/E Ratio
--
P/B Ratio
3.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
1.3
-
Debt to Equity
0.6
-
Book Value
$--
-
EPS
$-1
-
Face value
--
-
Shares outstanding
154,500,966
10 Years Aggregate
CFO
$-1,014.95 Mln
EBITDA
$-1,294.81 Mln
Net Profit
$-1,534.00 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Coherus BioSciences (CHRS)
| 0.0 | 0.7 | -9.6 | 22.4 | -36.1 | -38.5 | -26.3 |
|
BSE Sensex*
| -10.1 | -2.5 | 2.0 | -5.0 | 5.2 | 5.7 | 10.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Coherus BioSciences (CHRS)
| 2.9 | -58.3 | -58.0 | -50.4 | -8.2 | -3.5 | 99.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Coherus BioSciences (CHRS)
|
1.4 | 217.9 | 50.9 | -131.0 | -298.5 | -214.9 | -- | 3.7 |
| 85.4 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 267.3 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 71.9 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 58.5 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 109.7 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 369.2 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 546.9 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 593.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 357.5 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Coherus BioSciences (CHRS)
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating... factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. It also has a clinical collaboration agreement with Zumutor Biologics Inc. for the development of LOQTORZI with ZM0008 as a treatment for cancer patients. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California. Read more
-
Chairman, President & CEO
Mr. Dennis M. Lanfear
-
Chairman, President & CEO
Mr. Dennis M. Lanfear
-
Headquarters
Redwood City, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Coherus BioSciences (CHRS)
What is the current share price of Coherus BioSciences Inc (CHRS) Today?
The share price of Coherus BioSciences Inc (CHRS) is $1.42 (NASDAQ) as of 02-Sep-2026 16:00 EDT. Coherus BioSciences Inc (CHRS) has given a return of -36.13% in the last 3 years.
What is the current PB & PE ratio of Coherus BioSciences Inc (CHRS)?
Since, TTM earnings of Coherus BioSciences Inc (CHRS) is negative, P/E ratio is not available.
The P/B ratio of Coherus BioSciences Inc (CHRS) is 3.72 times as on 28-Aug-2026, a 28 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-1.00 |
2.80 |
2024 |
5.59 |
-1.21 |
2023 |
-1.56 |
-1.92 |
2022 |
-2.12 |
-4.49 |
2021 |
-4.27 |
12.55 |
What is the 52 Week High and Low of Coherus BioSciences Inc (CHRS)?
The 52-week high and low of Coherus BioSciences Inc (CHRS) are Rs 2.62 and Rs 1.09 as of 03-Sep-2026.
What is the market cap of Coherus BioSciences Inc (CHRS)?
Coherus BioSciences Inc (CHRS) has a market capitalisation of $ 218 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Coherus BioSciences Inc (CHRS)?
Before investing in Coherus BioSciences Inc (CHRS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.